10.1007/s00134-024-07404-9
10.1007/s00134-024-07404-9 · doi-reference
LBO-002 Plasma exchange with albumin 5% significantly increases 90-day overall survival in acute-on-chronic liver failure: topline results of the APACHE trial
10.1016/s0168-8278(26)00306-5 · doi-reference
High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial
10.1016/j.jhep.2015.08.018 · doi-reference
Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia
10.1007/s12072-024-10773-4 · doi-reference
Plasma exchange for acute and acute-on-chronic liver failure: A systematic review and meta-analysis
10.1097/lvt.0000000000000231 · doi-reference
Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure
10.1016/j.jhep.2023.03.013 · doi-reference
Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis
10.1186/s13613-020-00795-0 · doi-reference
Liver Transplantation in the Context of Acute-On-Chronic Liver Failure (ACLF): Where Do We Stand in 2025?
10.3389/ti.2025.14752 · doi-reference
Liver transplantation for acute-on-chronic liver failure
10.1016/s2468-1253(23)00363-1 · doi-reference
Liver transplantation for critically ill cirrhotic patients: Stratifying utility based on pretransplant factors
10.1111/ajt.15852 · doi-reference
The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure
10.1016/j.jhep.2023.05.028 · doi-reference
Long-term outcome following liver transplantation of patients with ACLF grade 3
10.1016/j.jhep.2024.06.039 · doi-reference
Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation
10.1053/j.gastro.2018.12.007 · doi-reference
Effects of granulocyte-colony stimulating factor (G-CSF) on stem cell mobilization in patients with liver failure
10.1016/j.ejim.2016.09.006 · doi-reference
Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure
10.3748/wjg.v19.i7.1104 · doi-reference
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)
10.1016/j.jhep.2021.07.033 · doi-reference
10.1053/j.gastro.2011.11.027
10.1053/j.gastro.2011.11.027 · doi-reference
10.1002/hep.30794
10.1002/hep.30794 · doi-reference
10.1111/liv.14936
10.1111/liv.14936 · doi-reference
10.1016/j.jhep.2021.09.003
10.1016/j.jhep.2021.09.003 · doi-reference
Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation
10.1002/ncp.10451 · doi-reference
An Open-label Randomized Controlled Trial of Early Initiation of Nasogastric Feeding After Endotherapy in Variceal Bleeding: A Proof-of-concept Study
10.1016/j.jceh.2023.07.413 · doi-reference
10.1097/ccm.0000000000001525
10.1097/ccm.0000000000001525 · doi-reference
10.1016/j.jhep.2018.06.024
10.1016/j.jhep.2018.06.024 · doi-reference
Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis
10.1016/j.jhep.2023.05.022 · doi-reference
Evaluation of the transplantation of ACLF grade 3 model (TAM) in the multicenter French experience
10.1097/lvt.0000000000000111 · doi-reference
Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis
10.1016/j.jhep.2022.07.014 · doi-reference
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis
10.1097/hep.0000000000001252 · doi-reference
10.1016/j.jhep.2022.06.001
10.1016/j.jhep.2022.06.001 · doi-reference
Ammonia measurement in cirrhosis: International Delphi consensus recommendations from ISHEN
10.1016/j.jhep.2026.03.020 · doi-reference
L‐ornithine L‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial
10.1002/hep.32255 · doi-reference
Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial
10.14309/ajg.0000000000002575 · doi-reference
10.1056/nejmoa0907893
10.1056/nejmoa0907893 · doi-reference
10.1136/flgastro-2025-103330
10.1136/flgastro-2025-103330 · doi-reference
Liver Failure, Hepatic Encephalopathy, and Infection Contribute to Mortality Risk in a Global Cirrhosis Cohort
10.1016/j.cgh.2025.06.021 · doi-reference
10.1111/liv.12257
10.1111/liv.12257 · doi-reference
10.1002/hep.26980
10.1002/hep.26980 · doi-reference
10.1016/j.jhep.2024.03.031
10.1016/j.jhep.2024.03.031 · doi-reference
Acute kidney injury in patients with acute-on-chronic liver failure: clinical significance and management
10.23876/j.krcp.22.264 · doi-reference
10.1002/hep.30592
10.1002/hep.30592 · doi-reference
